Spray dried glyceryl monooleate-magnesium trisilicate dry powder as cubic phase precursor

International Journal of Pharmaceutics

Volumn 323, Issue 1-2, 2006, Pages 18-26

  Shah, Manish H ^a   Biradar, Shailesh V ^a   Paradkar, Anant R ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Analgesic activity; Anti inflammatory activity; Cubic phase precursor; Glyceryl monooleate; Spray drying

Indexed keywords

DICLOFENAC; GLYCEROL OLEATE; MAGNESIUM TRISILICATE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTENT ANALYSIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG TRANSFORMATION; DRY POWDER; FEMALE; HYDRATION; IMAGE ANALYSIS; MALE; MICROSCOPY; NONHUMAN; PARTICLE SIZE; PHASE TRANSITION; POLARIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; SOLID STATE; SPRAY DRYING; VISCOMETRY; WATER TRANSPORT;

ANIMALS; BIOLOGICAL AVAILABILITY; CARRAGEENAN; DELAYED-ACTION PREPARATIONS; DICLOFENAC; DRUG DELIVERY SYSTEMS; EDEMA; FEMALE; GLYCERIDES; MAGNESIUM SILICATES; MALE; MICROSCOPY, ELECTRON, SCANNING; PAIN THRESHOLD; PARTICLE SIZE; PHASE TRANSITION; POWDERS; RATS; RATS, WISTAR; SOLVENTS; SPECTROPHOTOMETRY, INFRARED; VISCOSITY; WATER;

EID: 33748687575     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.05.040     Document Type: Article

References (21)

1. Broadhead J., Rouan E.S.K., and Rhodes C.T. The spray-drying of pharmaceuticals. Drug Dev. Ind. Pharm. 18 (1992) 1169-1206
2. Cornigan O.I. Thermal analysis of spray dried products. Thermochim. Acta 248 (1995) 245-248
3. Farkus E., Zelko R., Nemeth Z., Palinkas J., Morton S., and Raczs I. The effect of liquid crystalline structure on chlorehexidine diacetate release. Int. J. Pharm. 193 (2000) 239-245
4. Ferreira S.H. Prostaglandins. Aspirin-like drugs and analgesia. Nature New Biol. 240 (1972) 301-307
5. Ganem-Quintanar A., Quintanar-Guerrero D., and Buri P. Monoolein: a review of the pharmaceutical applications. Drug Dev. Ind. Pharm. 26 (2000) 809-820
6. International Conferences on Harmonization, Impurities, Guidelines for Residual Solvents, 1997. Q3C. Federal Register. 62, p. 67377.
7. Kim J.S., Kim H.K., Chung H., Sohn Y.Y., Kwon I.C., and Jeong S.Y. Drug formulations that form a dispersed cubic phase when mixed with water. Proc. Int. Symp. Control. Rel. Bioact. Mater. 27 (2000) 1118-1119
8. Kumar K.M., Shah M.H., Ketkar A., Mahadik K.R., and Paradkar A. Effect of drug solubility and different excipients on floating behavior and release from glyceryl mono-oleate matrices. Int. J. Pharm. 272 (2004) 151-160
9. Makai M., Csanyi E., Palinkas J., and Eros I. Structure and drug release of lamellar liquid crystals containing glycerol. Int. J. Pharm. 256 (2003) 95-107
10. Randall L.D., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissues. Arch. Int. Pharmacodyn. Ther. 113 (1957) 223-249
11. Rosevear F.B. The microscopy of the liquid crystalline neat and middle phases of soaps and synthetic detergents. J. Am. Oil. Chem. Soc. 31 (1954) 628-639
12. Sallam A.S., Khalil E., Ibrahim H., and Freij I. Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate. Eur. J. Pharm. Biopharm. 23 (2002) 343-352
13. Shah M.H., and Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int. J. Pharm. 294 (2005) 161-171
14. Shah J.C., Sadhale Y., and Chilukuri D.M. Cubic phase gels as drug delivery systems. Adv. Drug Deliv. Rev. 47 (2001) 229-250
15. Siekmann B., Bunjes H., Koch M.H.J., and Westesen K. Preparation and structural investigation of colloidal dispersions prepared from cubic monoglyceride-water phase. Int. J. Pharm. 244 (2002) 33-43
16. Spicer P.T., Small W.B., Lynch M.L., and Burns J.L. Dry powder precursors of cubic liquid crystalline nanoparticles (cubosomes). J. Nanoparticle Res. 4 (2002) 297-311
17. Szoka, F.C., Rolland, A., Wang, J., 1998. Dry powder formulations of polynucleotide complexes for inhalation delivery to the respiratory tract. US Patent 5,811,406, 22 September.
18. Vinegar R., Schreiber W., and Hugo R. Biphasic development of carrageenin oedema in rats. J. Pharmacol. Exp. Ther. 166 1 (1969) 96-103
19. Williams T.J., and Morley J. Prostaglandin as potentiators of increased vascular permeability in inflammation. Nature 246 (1973) 215-217
20. Williams T.J., and Peck M.J. Roll of prostaglandin-mediated vasodilatation in inflammation. Nature 270 (1977) 530-532
21. Winter C.A., Risley E.A., and Nuss C.W. Carrageenin-induced oedema in hind paw of the rats as an assay for anti-inflammatory drugs. Proc Soc. Exp. Biol. Med. 111 (1962) 544-547